Wajdie Ahmad

Wajdie Ahmad is a Biopharmaceutical executive with over 20 years of industry experience. Most recently Mr. Ahmad served as the co-founder and Chief Operating Officer of Bonti from its inception in 2015 until the company was acquired by Allergen (NASDAQ:AGN) in October 2018 for the upfront payment of $195M (> 6x multiple on invested capital in 3 years) and subsequent milestone payments. At Bonti, Mr. Ahmad was tasked with building and managing the Finance, HR, Legal, IT, R&D operations along with the company’s clinical programs. In addition, Mr. Ahmad was instrumental in helping to raise over $36M in three structured financing rounds. Prior to Bonti, Mr. Ahmad worked at Allergan for over 13 years in various roles with increasing responsibility within the Biologics manufacturing and development groups, focusing on the development, characterization, manufacturing and commercializing of neurotoxins, which includes Botox and other biologics programs. Mr. Ahmad received his B.S. in Biology from the University of California, Riverside, and his M.B.A. in Management from the University of California, Irvine.